Form 4: Nurix Therapeutics Chief Scientific Officer, Gwenn Hansen, Executes Stock Transactions

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, engaged in multiple stock transactions on January 30, 2025, including the vesting of restricted stock units and sales to cover tax obligations.

Summary

• Gwenn Hansen, the Chief Scientific Officer of Nurix Therapeutics, executed several transactions involving the company's stock on January 30, 2025.
• These transactions included the vesting of 3,207, 2,000, and 3,750 restricted stock units (RSUs), which converted into common stock.
• A total of 3,357 shares were sold at a weighted average price of $19.8068, with prices ranging from $19.28 to $20.275.
• An additional 333 shares were sold at a weighted average price of $20.3256, with prices ranging from $20.28 to $20.39.
• These sales were mandated by the company's policy to cover tax withholding obligations associated with the vesting of RSUs and do not represent discretionary trades by Ms. Hansen.
• Following these transactions, Ms. Hansen beneficially owns 55,937 shares of common stock and 33,750 restricted stock units.

Sentiment

Score: 7

Explanation: The document is neutral in sentiment, as it primarily reports routine stock transactions by an executive. There are no indications of positive or negative implications for the company's performance or outlook.

Management Comments

• The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This is a standard Form 4 filing, which is common for publicly traded companies when insiders execute stock transactions. It reflects the typical process of vesting and selling shares to cover taxes.

Comparison to Industry Standards

• The vesting schedule of the RSUs, with quarterly vesting over three to four years, is a common practice in the biotechnology industry for employee equity compensation.
• The 'sell to cover' mechanism for tax obligations is also a standard practice to simplify tax handling for employees receiving equity compensation.
• Companies like Amgen, Gilead, and Regeneron also use similar vesting schedules and tax withholding mechanisms for their employees.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they involve the sale of shares by an executive to cover tax obligations.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Nurix Therapeutics, Gwenn Hansen, restricted stock units, RSUs, stock transactions, Form 4, insider trading, tax withholding, equity incentive plans